FIG. 2.
HUCBC treatment results in decreased Aβ and increased anti-amyloidogenic APP processing. Brain homogenates from both 6- and 10-month treatments were evaluated using Aβ ELISA and immunoblotting analyses. These analyses show decreased levels of both soluble (a, b) and insoluble (c, d) Aβ40 and Aβ42 in brain homogenates prepared from PSAPP/HUCBC mice in both 6- and 10-month treatment groups when compared with PSAPP/PBS controls [n=10 (5♀/5♂)]. A t-test revealed a significant difference between PBS-injected and HUCBC-infused conditions, in both soluble Aβ40,42 and insoluble Aβ40,42 [n=10 (5♀/5♂)]. Aβ species and β-CTF were analyzed in mouse brain homogenates from (e) 6-month treatment and (f) 10-month treatment group using monoclonal Aβ1–16 antibody (6E10). (g) Densitometry analysis shows the ratio of Aβ to β-actin. *P<0.05; ***P<0.001. Aβ, amyloid-β; ELISA, enzyme-linked immunosorbance assay; CTF, C-terminal fragment.